Finally An Osteoporosis Prescription That Will Help Inhibit Bone Loss
Amgen NASDAQ: AMGN pharmaceutical company just announced positive performance results for denosumab Pivotal Postmenopausal Osteoporosis Trial.
Trial met primary endpoint of Reducing new vertebral fractures and secondary endpoints of reducing time to first non-vertebral and hip fractures; adverse events similar to placebo. The past president of the National Osteoporosis Foundation Stated, ” I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients.”
Denosumab is the premier fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts the cells that break down bone). Denosumab is being considered for its ability to inhibit all stages of osteoclast activity by a targeted mechanism. Denosumab is being studied for a variety of bone loss conditions including rheumatoid arthritis, postmenopausal osteoporosis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its potential to delay bone metastases and inhibit and treat bone destruction across many stages of cancer.
Osteoporosis is often referred to as the “silent epidemic”, osteoporosis is a global problem illness, which is increasing in dominance as the world population both ages and increases. The World Health Organization (WHO) has recently identified osteoporosis as a priority health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical industry to help combat this terrible disease.
According to Amgen the financial burden of osteoporosis is comparable to as the “silent epidemi’ to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).
Pharmacist-clinical have been developing prescriptions drugs to help patient who experience serious side effects. These products are developed simultaneously the medications that aid in the treatment of the initial illness. The fact that research is available to help predict the potential effects and interactions drugs have with one another is outstanding.
These medicines are prescribed to prevent and treat osteoporosis. A few prescriptions slow the rate of bone loss or increase bone thickness. Even small amounts of new bone growth can reduce the danger of broken bones. It is important that you take calcium and vitamin D, eat well and exercise when you take osteoporosis prescriptions.
By: CF Thompson